跳至主要内容
临床试验/NCT06968832
NCT06968832招募中不适用

Project COMET: Hybrid Effectiveness-Implementation Trial of Massed PTSD Treatment in a Community Substance Use Program

Rutgers, The State University of New Jersey1 个研究点 分布在 1 个国家目标入组 168 人开始时间: 2025年9月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
168
试验地点
1
主要终点
Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

研究概览

简要总结

The goal of this clinical trial is to learn if Massed Prolonged Exposure Therapy (M-PE) can improve PTSD symptoms and reduce substance use in adults receiving intensive outpatient (IOP) treatment for substance use disorder (SUD). The main questions it aims to answer are:

  • Does M-PE reduce PTSD symptoms more effectively than trauma treatment as usual (TAU)?
  • Does M-PE reduce the number of days participants use substances?
  • How do patient-centered outcomes (such as depression, suicidal thoughts, and quality of life) differ between M-PE and trauma TAU?
  • Researchers will compare M-PE to treatment as usual to see if M-PE leads to better mental health and substance use outcomes and lower dropout rates.

Participants will:

  • Attend multiple therapy sessions per week (M-PE) or receive usual care
  • Complete assessments at baseline, during treatment, end-of-treatment, 1-month, 3-month, and 6-month follow-up
  • Share feedback through surveys and interviews about their experience in the program

详细描述

Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly).

M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in outpatient care. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M-PE delivery in of SUD IOP program in improving PTSD and other mental health outcomes is the necessary next step in this critical research.

The mixed-method two-group Hybrid Type I effectiveness-implementation randomized clinical trial (RCT) aims to determine the effectiveness of M-PE delivery in SUD IOP in reducing dropout rates and improving outcomes as compared to trauma treatment as usual (TAU).

The specific aims are to 1) Compare the effectiveness of M-PE to trauma TAU in IOP SUD treatment in impacting PTSD symptoms and Percent days use of primary substance; 2) Explore differences in treatment arms on patient-centered outcomes, including: a) days use of other (non-primary) substances, b) depressive symptoms, c) functioning, c) quality of life (QoL), e) suicidal ideation, and f) participant satisfaction; 3) Examine gender as a moderator and changes in trauma-related cognitions, cravings, and their temporal association as mediators of change in PTSD and substance use; and 4) Conduct a mixed-method process evaluation to understand patients', providers', and clinical stakeholders' experiences with M-PE, explore barriers and facilitators to integrating M-PE into IOP SUD treatment, and identify strategies for widespread implementation.

Participants will include 168 male and female patients with any trauma type who are participating in IOP SUD program at Gateway Community Services, Inc. Assessments will occur at baseline, and will continue for the duration of treatment, at end-of-treatment, 1-month posttreatment, 3-months posttreatment, and 6-months posttreatment. We will conduct a mixed-method, multi-stakeholder process evaluation with patients, providers, and clinical leaders.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Enrolled in SUD treatment at Gateway Community Services
  • •Meet DSM-5 criteria for a SUD (Tobacco Use Disorder alone not sufficient for inclusion)
  • •Meet DSM-5 criteria for PTSD
  • •Able to give informed consent

排除标准

  • •severe cognitive impairment
  • •current suicidal or homicidal intent requiring immediate treatment
  • •current unstable psychotic or manic symptoms not attributable to SUD

研究组 & 干预措施

Massed Prolonged Exposure (M-PE) + Intensive Outpatient Program (IOP)

Experimental

Participants randomized to this arm will receive Massed Prolonged Exposure (M-PE) therapy, a gold-standard treatment for PTSD delivered multiple times per week over 2-4 weeks. M-PE will be integrated into the standard Intensive Outpatient Program (IOP) for substance use disorder (SUD) at Gateway Community Services, Inc. This arm is designed to evaluate the effectiveness of delivering M-PE concurrently with SUD treatment in improving PTSD symptoms, reducing substance use, and improving patient-centered outcomes.

干预措施: Massed Prolonged Exposure Therapy (M-PE) (Behavioral)

Trauma Treatment as Usual (TAU) - IOP with Trauma Skills Group

Active Comparator

Participants randomized to this arm will receive the standard Intensive Outpatient Program (IOP) for substance use disorder (SUD), which includes a weekly trauma skills group as part of usual care. This comparator arm allows for evaluation of whether M-PE enhances outcomes beyond those achieved through trauma-informed IOP care.

干预措施: Standard outpatient SUD care (Behavioral)

结局指标

主要结局

Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

时间窗: Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up

Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity

Time Line Follow back (TLFB)

时间窗: Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up

Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use

次要结局

  • Patient Health Questionnaire-9 (PHQ-9)(Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up)
  • Brief Psychosocial Functioning Inventory (B-IPF)(Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up)
  • Brief Substance Craving Scale (BSCS)(Baseline; End of Treatment (6 weeks post-randomization); 1-month (10 weeks), 3-month (18 weeks), and 6-month (30 weeks) post-randomization follow-up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Denise Aimee Hien

Helen E. Chaney Endowed Chair in Alcohol Studies; Distinguished Professor, Graduate School of Applied and Professional Psychology

Rutgers, The State University of New Jersey

研究点 (1)

Loading locations...

相似试验